Abstract
Atopic dermatitis is a common, chronic relapsing inflammatory skin disease. The complex of different interactions between individual genetic predisposition to atopic diseases (bronchial asthma, allergic rhino-conjunctivitis, and food or inhalant allergy(, environmental factors, epidermal barrier dysfunction and abnormalities of the immune system are involved.
The currently available therapeutics are limited. Over the last few years, new advances in the understanding of atopic dermatitis pathogenic mechanisms and inflammatory pathways have led to the identification of specific therapeutic targets and new molecules have been tested.
Biological target treatment seems to be very promising in the management of moderate-to-severe atopic dermatitis.